After questions surrounding funding, ReiThera reveals high antibody response for Covid-19 jab in PhII study

The Italian government saved drugmaker ReiThera’s Covid-19 candidate efforts in May when it threw its support and money behind the company’s own vaccine in the middle of a shortage. The move has appeared to pay off, as the company on Monday announced that Phase II trial data revealed high antibody responses after two doses.